PacBio Ships First Two Commercial Systems; Order Backlog Grows to 44

The firm anticipates $35 million in total revenue for full-year 2011, most of it from sales of the PacBio RS.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.